Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Progression

Tumor Progression

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

Development of the Lymphatic System

Development of the Lymphatic System

The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

IL-33 scripts cancer immunity.

Trends in immunology·2026

Same author

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.

Acta oncologica (Stockholm, Sweden)·2026

Same author

Cancer in disguise: a parasite within.

The EMBO journal·2026

Same author

Obesity enhances salt-sensitivity of blood pressure, independent of skin electrolytes, and more in female than in male ZSF1 rats.

American journal of physiology. Renal physiology·2025

Same author

The role of innate immune cells in modulating vascular dynamics in skin malignancies.

Biochimica et biophysica acta. Reviews on cancer·2025

Same author

Intestinal interstitial fluid isolation provides novel insight into the human host-microbiome interface.

Cardiovascular research·2025

Search research articles

Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8⁺ T Cells During LN Metastasis

Published on: January 26, 2024

Impaired lymphatic function accelerates cancer growth.

Eli Sihn Samdal Steinskog¹, Solfrid Johanne Sagstad¹, Marek Wagner¹

¹Department of Biomedicine, University of Bergen, Bergen, Norway.

|June 23, 2016

Summary

This summary is machine-generated.

Impaired lymphangiogenesis (lymphatic vessel formation) accelerates tumor growth by weakening anti-tumor immunity. Targeting IL-6 shows potential for inhibiting breast cancer progression.

Keywords:

Chy mice IL-6 cancer lymphangiogenesis tumor associated macrophages

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Mar 19, 2026

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8⁺ T Cells During LN Metastasis

Published on: January 26, 2024

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Published on: May 1, 2015

Area of Science:

Oncology
Immunology
Vascular Biology

Background:

Increased lymphangiogenesis is common in cancer, but the impact of impaired lymphatic vessel formation on tumor growth is unclear.
Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) signaling is crucial for lymphatic development.

Purpose of the Study:

To investigate the role of impaired lymphangiogenesis in early-stage tumor growth and anti-tumor immunity.
To explore the impact of reduced lymphatic function on the tumor microenvironment and immune cell infiltration.

Main Methods:

Orthotopic implantation of C3HBA breast cancer and KHT-1 sarcoma cell lines into Chy mice with impaired VEGFR-3 signaling and reduced lymphangiogenesis.
Analysis of tumor growth, peritumoral lymphangiogenesis, lymphatic washout, and immune cell populations (macrophages, adaptive immunity).
Assessment of cytokine profiles and evaluation of IL-6 blockade therapy (tocilizumab) in breast cancer models.

Main Results:

Chy mice exhibited accelerated tumor growth in both cancer models, associated with reduced peritumoral lymphangiogenesis.
Impaired lymphatic washout and reduced macrophage infiltration were observed in Chy mice, with a shift towards an M2 macrophage phenotype.
While adaptive immunity was unaffected, innate immune responses were impaired, and elevated IL-6 levels in tumors led to growth inhibition upon tocilizumab treatment.

Conclusions:

Impaired lymphangiogenesis weakens anti-tumor immunity and promotes tumor growth in early cancer development.
The study highlights the intricate relationship between lymphatic function, the tumor microenvironment, and immune evasion.
Targeting IL-6 presents a potential therapeutic strategy for cancers with compromised lymphatic function.